Actual Medicinal Product (AMP) Lamictal 25mg tablets (GlaxoSmithKline UK Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
No stability data available but no theoretical concerns with product.
- Provenance
-
This recommendation is based on the products Lamictal 25mg tablets (GlaxoSmithKline UK) and lamotrigine 25mg tablets (Aurobindo Pharma - Milpharm Ltd).
- Generic
- Lamotrigine
- Formulation
- Lamotrigine 25mg tablets
-
Lamotrigine
-
Lamotrigine 25mg tablets
-
Lamictal 25mg tablets (GlaxoSmithKline UK Ltd)
-
-
Lamotrigine 25mg dispersible tablets sugar free
Lamotrigine 200mg dispersible tablets sugar free